Telesis Bio, Inc (TBIO) Fair Value & Analysis
Healthcare · US · Market cap $1.8K
Telesis Bio, Inc
TBIO · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $74.85 to $0.0010 (−100.0%) since Jun 24, 2026. Share price −5.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0000 – $0.0060 · fair‑value band $0.0010 – $0.0010 · the $0.0010 price screens above the $0.0010 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Telesis Bio, Inc (TBIO) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0010 — implying the stock looks roughly 0.4% overvalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $17.0M. Revenue declined 61.8% year over year. Net debt stands at $32.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic …
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Telesis Bio, Inc reported revenue of $27.5M in FY2023 versus $4.8M in FY2019, a compound +54.7%/yr. Reported net income was −$47.7M in FY2023.
Is TBIO fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.50 | €33.99 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Telesis Bio, Inc (TBIO) undervalued?
What is the fair value of TBIO?
What is the quality score of TBIO?
What is the revenue of Telesis Bio, Inc (TBIO)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.